2119583-24-1: Nilotinib Ethylimidazole Analog
Nilotinib Ethylimidazole Analog (CAS No: 2119583-24-1) is an impurity present in Nilotinib which is a second-generation tyrosine kinase inhibitor indicated for the treatment of patients with chronic myeloid leukemia in the chronic phase and accelerated phase who are resistant to or intolerant of prior imatinib therapy.
Additional information on CAS 2119583-24-1
VE008151
2119583-24-1
C29H24F3N7O
543.54 g/mol
Nilotinib
N-(3-(4-Ethyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)benzamide
N/A
Kondra, S. B., et al. “A Validated Stability-Indicative UPLC Method for Nilotinib Hydrochloride for the Determination of Process-Related and Degradation Impurities.” Journal of Chromatographic Science, vol. 52, no. 8, Sept. 2013, pp. 880–85, https://doi.org/10.1093/chromsci/bmt134.?Hughes, Timothy, et al. “Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase.” Journal of Clinical Oncology, vol. 27, no. 25, Sept. 2009, pp. 4204–10
In-stock
